Associate Professor of Neurology, Associate Professor of Neurological Surgery, Associate Professor of Oncology, Johns Hopkins University School of Medicine; Director, The Johns Hopkins Comprehensive Neurofibromatosis Center
Neurology
Dr. Jaishri O. Blakeley, MD
|
|
Give Review
Jaishri Blakeley practices Neurology. She went to Baylor College of Medicine. She received 1 awards: "CMS Meaningful Use Stage 1 Certification". Jaishri Blakeley is a published MD. She has 48 papers published. The most current publication "Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1." She is registered with Medicare.
Publications
- Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and Schwannomatosis.
- 18F-FDG PET/CT Qualitative and Quantitative Evaluation in Neurofibromatosis Type 1 Patients for Detection of Malignant Transformation: Comparison of Early to Delayed I...
- First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced Cancer and glioma.
- How Critical Is the Blood-Brain Barrier to the Development of Neurotherapeutics?
- Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with ...
- Clinical response to bevacizumab in Schwannomatosis.
- Update from the 2013 international neurofibromatosis conference.
- Conventional and Functional MR Imaging of Peripheral Nerve Sheath Tumors: Initial Experience.
- CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and Schwannomatosis toward the development of effective therapies.
- Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple Schwannomas.
- Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
- Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.
- Hearing and facial function outcomes for neurofibromatosis 2 clinical trials.
- Achieving consensus for clinical trials: The REiNS International Collaboration.
- Limited detection of IgH gene rearrangements in plasma of patients with primary central Nervous system lymphoma.
- Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1.
- Histopathological correlates with survival in reoperated glioblastomas.
- Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
- Schwannoma in neurofibromatosis type 1: a pitfall for detecting malignancy by metabolic imaging.
- Multiple resections for patients with glioblastoma: prolonging survival.
- Plexiform Nerve sheath tumor or vascular malformation-role of advanced MR neurography and diffusion tensor imaging.
- Three-dimensional amide proton transfer MR imaging of Gliomas: Initial experience and comparison with gadolinium enhancement.
- Optimizing biologically targeted clinical trials for neurofibromatosis.
- Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.
- Anatomic MR Imaging and Functional Diffusion Tensor Imaging of Peripheral Nerve Tumors and Tumorlike Conditions.
- Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas.
- Development of drug treatments for neurofibromatosis type 2-associated vestibular Schwannoma.
- Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
- Tissue concentration of systemically administered antineoplastic agents in human Brain tumors.
- What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.
- Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular Schwannoma.
- Analysis of dynamics and propagation of parietal cingulate seizures with secondary mesial temporal involvement.
- Practical data acquisition method for human Brain tumor amide proton transfer (APT) imaging.
- Evaluation of human Brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches.
- Management of pineal region Tumors.
- Drug delivery to Brain tumors.
- Case 5: altered mental status and fever after resection of glioblastoma multiforme.
- Chemotherapy with cytotoxic and cytostatic agents in Brain cancer.
- Anaplastic oligodendroglioma.
- Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
- Microdialysis for assessing intratumoral drug disposition in Brain cancers: a tool for rational drug development.
- Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides.
- Quantitative description of the asymmetry in magnetization transfer effects around the water resonance in the human Brain.
- Thrombolytic therapy for acute ischemic stroke.
- Effect of blood Brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study.
- Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic Astrocytomas in adults with NF1.
- Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).
Schools
Baylor University
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Ataxia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Central Nervous System Lymphoma
- Cerebrovascular Disease
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Johns Hopkins University -
Baylor College of Medicine
Hospital
-
Johns Hopkins Bayview Medical Center -
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1497801815 | |
| NPPES Provider LastName | BLAKELEY | |
| NPPES Provider FirstName | JAISHRI | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Neurology | |
| Total Claim Count | 195.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497801815 |
| Last Name Of The Provider | BLAKELEY |
| First Name Of The Provider | JAISHRI |
| View All |
Similar Doctors
|
|
Dr. Bonnie J. Gerecke, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven L. Strauss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ahmet Hoke, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Paul S. Fishman, MD |
|
|
Dr. Ellen M. Mowry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory Krauss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey Rothstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher A. Stack, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Ernst F L. Niedermeyer |
|
|
Dr. Adrian W. Clayton, DO
This Doctor is OpenDoctor Recommended.
|